# A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Study · id `cardio:ct-nct06034743` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06034743](<https://clinicaltrials.gov/study/NCT06034743>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06034743

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 796 participants.

## Technical summary

Registry record NCT06034743. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2025-05-21 (actual). Results posted on 2026-07-30.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 796 participants (enrolled count; ClinicalTrials.gov record NCT06034743, source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)
- Started: 2023-11-22 (actual) (ClinicalTrials.gov record NCT06034743, source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2025-05-21 (actual) (ClinicalTrials.gov record NCT06034743, source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)
- Completion: 2025-10-10 (actual) (ClinicalTrials.gov record NCT06034743, source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)
- Results first posted: 2026-07-30 (ClinicalTrials.gov record NCT06034743, source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Bulgaria; Canada; Czechia; Denmark; France; Germany; Hungary; India; Israel; Italy; Japan; Malaysia; Netherlands; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06034743, source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06034743-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
- Acronym: BaxHTN
- Condition: Uncontrolled Hypertension
- Condition: Resistant Hypertension
- Intervention (Drug): Baxdrostat
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension (`cardio:pubmed-40888730`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 89d9a5ec6836f22a1f4b6a90442e5b148a852670e94931eb2bb762c15e1ddb7a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
